The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An update in CLL from EHA 2020

Jul 14, 2020

During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub spoke to Susan O'Brien, University of California Irvine, Orange, US, who discussed the latest updates on chronic lymphocytic leukemia (CLL) from EHA 2020.

An update in CLL from EHA 2020

Highlights in CLL from this year's virtual EHA Annual Congress include

  1. Update (~39 months) from the CLL-14 trial (NCT02242942), comparing the safety and efficacy of obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL
  2. Update from the CAPTIVATE trial (NCT02910583) evaluating ibrutinib + venetoclax in patients with treatment-naïve CLL
  3. Acalabrutinib for the treatment of relapsed CLL